标题:BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
作者:Li, Xuanzong; Wang, Shijiang; Li, Butuo; Wang, Zhen; Shang, Shuheng; Shao, Yang; Sun, Xindong; Wang, Linlin
作者机构:[Li, Xuanzong] Univ Jinan, Shandong Acad Med Sci, Sch Med & Life Sci, Jinan, Shandong, Peoples R China.; [Li, Xuanzong; Wang, Shijiang; Li, Butuo; S 更多
通讯作者:Wang, LL
通讯作者地址:[Wang, LL]Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Radiat Oncol, 440 Ji Yan Rd, Jinan 250117, Shandong, Peoples R China.
来源:TARGETED ONCOLOGY
出版年:2018
卷:13
期:4
页码:517-523
DOI:10.1007/s11523-018-0573-2
摘要:The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. However, resistance inevitably occurs, and the mechanisms leading to treatment failure need to be further investigated. The B-cell lymphoma 2 (BCL-2)-like 11 (BIM) deletion polymorphism, which occurs at a frequency of 21% in East Asians but is absent in African and European populations, has been associated with resistance to first-generation EGFR TKIs, such as gefitinib and erlotinib; and is a poor prognostic factor for NSCLC patients with EGFR mutations. Nevertheless, the significance of this BIM deletion polymorphism in the resistance to osimertinib has not been reported. Here, we show for the first time that a NSCLC patient harboring the EGFR L858R/T790M mutations, as well as the BIM deletion polymorphism, exhibited poor clinical outcomes with osimertinib treatment. This result suggests that the BIM deletion polymorphism might have prognostic value for determining NSCLC patient outcomes following osimertinib treatment.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048548068&doi=10.1007%2fs11523-018-0573-2&partnerID=40&md5=225dbc9a0fbaa4b02184f787f68a91cf
TOP